Updated information: due to a schedule conflict, this event will be postponed to August. 19 (Saturday) at 6:30-9pm. Chairman will not be able to make it but Dr. Sun (global research VP) will still give the speech, and meet people with projects and looking for a job.
High level officer from Tasly Group (top 10 pharmaceutical companies in China) will be in the bay area. Tasly is looking for project collaboration and talent recruitment opportunities (details below). In addition, there will be a seminar on FDA/CFDA regulatory affairs.
If you would like to present for 5min in the areas that Tasly is interested, please fill out the google form below. We will get back to you. https://docs.google.com/forms/d/e/1FAIpQLSdAPRhwIThhYwewc0gxf73HjIssy5YgKnuDFxy6R5KbT3jMJA/viewform
If you apply for the job positions, please bring your resume and attend the meeting.
If you just want to attend the seminar, we welcome you as well.
Please register if you plan to show up no matter to present, to apply for job, or to attend the seminar.
If you have any questions, please email at firstname.lastname@example.org
7-8pm presentation: Active Adaptation and Fusion of Regulatory: Challenges and Opportunities for Pharmaceutical Companies in China and the U.S. by former FDA high-level officer and current global research VP of Tasly Group
8-9pm project presentation (5min each)
Tasly Group Introduction
Tasly Holding Group was founded in 1994, a high-tech and globalized enterprise focused on Great Health industry, with pharmaceutical industry as its core business; health care industry, health management and service industry as its paralleling businesses. The corporate philosophy of Tasly is ‘To pursue harmonization between human and nature, to improve life quality’; the corporate mission is ‘To share the joy of health with all’. Tasly is committed to build the best modern and international TCM brand, and to become a leading brand in Great Health industry. Tasly’s total capital has reached 49.2 billion RMB and the sales volume is 30.4 billion RMB in 2016.
Tasly has developed a series of products, including modern TCM, chemical medicines, as well as biological drugs. The signature product Compound Danshen Dripping Pills has successfully completed FDA Phase III clinical trials in 2016; and it is the first compound Chinese herbal drug which have completed FDA-regulated phase-III clinical trials and proved that it is safe and effective in the treatment of chronic stable angina. Series of Tasly products are currently in the pipeline under globalization development.
Dr. Henry H. Sun Introduction
Dr. Sun received his PhD in Clinical Pharmacology and Biopharmaceutics from the University of Connecticut in 1993.He served at the US FDA as a regulatory reviewer, then was promoted to one of the top-ranked agency-level Expert Scientist/Reviewer in 2000. In 2006，Dr. Sun joined Tasly Group Co. Ltd. as Vice President. Dr. Sun is currently global research VP of Tasly, President of Tasly Pharmaceuticals Inc., and founder and CEO of Aexon Research, Inc., a full service global CRO firm focusing on regulatory consultations and clinical research programs. Dr. Sun also serves at Tianjin University as a Professor and Department Head of Regulatory Science and Clinical Pharmacology, and is a Special Professor at the School of Medicine, University of Nottingham of UK, Adjunct Research Scientist at the NIH of USA.
- Disease areas：cardiovascular diseases, cancer, hepatobiliary & digestive diseases, gynecological & pediatric diseases, neurological diseases
- Type: innovative new drugs (NMEs, biosimilar), innovative diagnostic techniques, innovative technology platforms (drug delivery, analytical method, research model, etc.), novel therapeutic program/scheme, small to medium biotech companies (investment, M&A), research & marketing collaboration
- Management: senior executive, senior BD, senior marketing & sales (in Washington DC area or in China including Tianjin, Shanghai Zhangjiang, and Jiangsu Hauian)
- Technical experts: chemical and biological drug research (in Tianjin, Shanghai Zhangjiang or in Jiangsu Huaian), global clinical research, and others who specialized in certain drug research areas (in Washington DC area)
registration for free – $0 (USD)